Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer
Authors:
- 31 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 35 (8) , 741-751
Abstract
Objective: To explore the mechanism of anlotinib resistance in thyroid carcinoma. Methods: We constructed an anlotinib-resistant thyroid carcinoma cell line and observed the effect of drug resistance on the functional activity of these cell lines. Transcriptome sequencing and metabolomic sequencing combined with biosynthesis analysis were used to explore and screen possible drug resistance regulatory pathways. Results: Through transcriptomic sequencing analysis of drug-resistant cell lines, it was found that the differentially expressed genes of drug-resistant strains were enriched mainly in the interleukin 17, transforming growth factor-β, calcium, peroxisome proliferator activated receptor, and other key signaling pathways. A total of 354 differentially expressed metabolic ions were screened using liquid chromatography-mass spectrometry/mass spectrometry to determine the number of metabolic ions in the drug-resistant strains. The results of the Venn diagram correlation analysis showed that glutamate is closely related to multiple pathways and may be an important regulatory factor of anlotinib resistance in thyroid carcinoma. In addition, eight common differentially expressed genes were screened by comparing the gene expression profiling interactive analysis database and sequencing results. Further quantitative real time polymerase chain reaction verification, combined with reports in the literature, showed that LPAR1 may be an important potential target. Conclusion: This is the first study in which the drug resistance of thyroid cancer to anlotinib was preliminarily discussed. We confirmed that anlotinib resistance in thyroid cancer promotes the progression of malignant biological behavior. We conclude that glutamate may be a potential factor for anlotinib resistance in thyroid cancer and that LPAR1 is also a potentially important target.Keywords
This publication has 33 references indexed in Scilit:
- A Gpr35-tuned gut microbe-brain metabolic axis regulates depressive-like behaviorCell Host & Microbe, 2024
- Targeted therapy and drug resistance in thyroid cancerEuropean Journal of Medicinal Chemistry, 2022
- Metabolic reprogramming in cholangiocarcinomaJournal of Hepatology, 2022
- Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicityCancer Immunology, Immunotherapy, 2020
- Modulating ROS to overcome multidrug resistance in cancerDrug Resistance Updates, 2018
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013JAMA, 2017
- Glutamate and its receptors in cancerJournal of Neural Transmission, 2014
- Glutamate: a truly functional amino acidAmino Acids, 2012
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Potential role of GABAA receptor subunit; GABRA6, GABRB2 and GABRR2 gene polymorphisms in epilepsy susceptibility and pharmacotherapy in North Indian populationClinica Chimica Acta, 2011